We value the intangible assets of pharmaceutical companies using discounted cash-flows and compare the value-relevance of these assets against prior intangible asset measures such as reported intangible assets and R&D capital. For pharmaceutical companies the accurate valuation of assets is important for raising funds. The study finds that discounted cash-flow valuation of intangible assets is preferred to reported intangibles and R&D capital in explaining market value. This is the first known study that values intangible assets using reported sales revenues and compares those valuations with input-based R&D capital valuation models.
Introduction
We value the drug patents produced by the world's largest pharmaceutical companies.
In business practice intangible asset valuation is unavoidable. Business valuers frequently undertake valuations of intangible assets for commercial and tax purposes using diverse inputs. We first value the drug patents of pharmaceutical companies using discounted cashflows. We then compare the value-relevance of these discounted cash flow measures to other intangible asset measures such as reported intangible assets and R&D capital.
We focus on intangible assets in the pharmaceutical industry for a number of reasons.
The pharmaceutical industry presents an intangible asset-rich sample of companies and highvalue blockbuster drugs. Second, pharmaceutical companies have similar product life-cycles, financial structure and operating expenses for the valuation of intangible assets. Importantly, the largest pharmaceutical companies voluntarily disclose drug product sales revenues enabling calculation of future cash flows, and the valuation method applies to a broader range of intangible assets.
There are three motivations for the study. To the best of our knowledge, this paper is the first to value internally-generated intangible assets in health care, and one of the very few to value intangible assets from income. Prior studies value intangible assets using a large number of different research designs that illustrate the problem of identifying relevant and verifiable information to value intangibles (Wyatt, 2008) . The valuation of intangible assets is arguably speculative rather than relevant for decision-making.
Second, the valuation of intangible assets is of substantial importance to pharmaceutical companies and health care.
The pharmaceutical industry is in the midst of one of the biggest patent cliffs with Pfizer's multi-billion-dollar blockbuster drug Lipitor losing patent protection in the US in late November 2011…other major branded drugs that lost patent protection in the past few months represent branded sales worth more than $15 billion. 1 Patents are important to appropriate the benefits of pharmaceutical innovation (Grabowski, 2002) . In addition, the revenue from patents is necessary to fund future research and raise funds. Intangible asset information benefits a range of parties such as investors and management. In addition banks and creditors typically have difficulty in assessing the financial position of companies with intangible assets. The value of intangible assets is particularly of interest to pharmaceutical companies undergoing industry change, and facing takeover and merger activity.
Third, we explore whether drug sales, reported intangibles and R&D expenses are useful for valuing pharmaceutical companies. The value-relevance of internally generated pharmaceutical patents provides evidence on the desirability of valuing intangible assets, either for intangible asset standards, or specifically for health care companies as a sector. A primary focus of the Financial Accounting Standards Board (FASB) and other standard setters is equity investment (Barth, Beaver and Landsman, 2001 ).
The key finding is that patent valuation by discounted cash flows dominates valuation by reported intangible assets and R&D expenditure in explaining the market value of the company. Further, the valuation of pharmaceutical patents by discounted cash flows is valuerelevant for companies reporting drug product sales that exceed one third of total sales revenue.
We contribute to the valuation of intangible assets and to the relevance of pharmaceutical intangible assets. We provide evidence that the presentation of product sales revenue information assists the valuation of assets and the price discovery of stocks. We also provide evidence that the discounted cash flow method of valuing intangible assets is more useful in assessing the financial position of pharmaceutical companies than other methods of valuation. The next section reviews the literature and develops the hypotheses. Section three outlines the research methodology, section four reports the results, and section five concludes the paper.
Literature and Hypothesis Development
According to pharmaceutical financial reports internal research and development costs are expensed as incurred, and only acquired intangible assets are recognised as assets. This results in the undervaluation of pharmaceutical intangible assets. In addition, the general nature of intangibles leads to non-standard and noisy measurement methods of their value:
resource input measures, output measures, management reported measures and exotic researcher metrics (Wyatt, 2008; Hunter, Webster and Wyatt, 2012) . The failure to recognise intangible assets also puts pressure on valuation analysts to use diverse information (Damodaran, 2009) . As a result, the use of non-standard valuation information outside the firm reduces the comparability and reliability of the valuations.
Objections to the capitalisation of intangible outgoings also centre on the uncertainty associated with the economic benefits of intangibles (Lev and Zarowin, 1999) . This uncertainty is partially resolved when property rights attach to investment outputs (Wyatt, 2008; Hunter, Webster and Wyatt, 2012) . The patent outputs of pharmaceutical R&D contain property rights that resolve the uncertainty of their future economic benefits.
Chemical and pharmaceutical patents are more valuable than patents in other industries (Bessen, 2008) . Prior technology studies often estimate the value of intangible assets by capitalising R&D expenditures (Lev and Sougiannis, 1999; Chan Lakonishok and Sougiannis, 2001) . A common output of R&D in pharmaceuticals is patents, although simple counts of patents are not useful for valuation (Griliches, 1990) . Nevertheless, drug patents generate cash flows that can be estimated, discounted and valued.
Intangible assets are important to pharmaceutical companies. The discovery and development of new drugs is a very lengthy and costly process (DiMasi, Hansen, Grabowski and Lasangna 1991) . The pharmaceutical patents give the owner the exclusive use of technology to produce products and services (Grabowski, 2002) . Pharmaceutical patents are also critical to financial performance in the biotechnology sector. First, the distribution of returns to new drug innovations is highly skewed. Roughly one half of the present value from a sample of 118 compounds between 1990 and 1994 is accounted for by the top-ranked decile of new drug introductions. Median new drug returns do not cover the R&D costs of the average compound (Grabowski, Vernon and DiMasi, 2002) . R&D costs are rising, and higher real R&D costs have been cited as one of the main factors underlying the recent trend toward more mergers and industry consolidation (DiMasi, Hansen and Grabowski, 2003) .
In essence, a minority of blockbuster drugs fund much pharmaceutical R&D.
Blockbuster drugs with annual sales in excess of $US 1billion increased in number from six to 52 between 1997 and 2006 (Aitken, Berndt and Culter 2009 Berndt and Aitken, 2010) . In this study, we exploit a rare opportunity to value intangible assets with information on drug product sales revenues, and the valuation information is expected to be useful to numerous users of financial information.
The Valuation of Pharmaceutical Intangibles
Individual patents are generally valued by cost, market, or income based methods which include discounted cash flows. Valuation models using input expenditures on intangibles arguably lack theory for asset valuation (Holthausen and Watts, 2001 ). In contrast, asset valuation using cash flows is a model widely accepted in valuation theory and practice (Ohlson, 1995; Dechow, Kothari and Watts, 1998; Damodaran, 2009) . Further, the forecast of future income from a patent is an improvement on estimating the market value or cost of the patent (Pitkethly, 1997 To assess the resulting patent valuations by discounted cash flows, we examine reported intangible assets and also value pharmaceutical intangibles by capitalising R&D expenditures to estimate R&D capital (Lev and Sougiannis, 1999; Chan Lakonishok and Sougiannis, 2001) . A large number of studies test the value-relevance of financial and nonfinancial information in the biotechnology sector (Ely et al 2003; Xu et al, 2007; Yang, 2008) . Virtually all studies show that book value of equity and R&D expenditure are positively associated with market value of equity (Callen, Gavious and Segal, 2010 
Research Method
In addition to using the reported value of intangible assets, we value pharmaceutical intangibles using two methods: discounted free cash flows (FCFs) are estimated from product sales revenues, and R&D capital is calculated from R&D expenditures. The discounted FCFs have a number of inputs detailed below. Following valuation, the intangible asset estimates are tested for value-relevance and their value-relevance is compared using Vuong and Clarke tests.
Valuation of Pharmaceutical Patents
To value pharmaceutical patents we first use the following inputs and outputs to estimate free cash flows:
• The estimated life of the patent
• The drug product revenue life cycle
• Cost of capital
• Forecasted drug product sales revenues
• Contribution margin
• Post-approval R&D expense
• Capital investment
• Tax expense
Drug Product Sales Revenues
After calculating expected cash flows, we estimate n the remaining useful life of the patents.
The distribution of drug product sales revenue peaks a number of years after drug approval and declines at an accelerated rate. Major drug products coming off patent in the 1990s provide four average percentage declines of 31, 28, 20 and 20% respectively (Grabowski Vernon and DiMasi, 2002) . As a result, the distribution of drug product revenues is non-linear. The distribution of drug product revenue is illustrated in three stages in Figure   1 .
Figure 1: Expected Distribution of Drug Product Sales Revenues
A discount rate r reflecting the cost of capital is used to discount the expected cash flows. The cash flows are discounted at the cost of equity since pharmaceutical companies typically have average debt levels of 10% of market value (DiMasi et al, 2003) . The discount rate for pharmaceutical companies with drugs at final stages of development is 9% to 10% based on a capital asset pricing model (CAPM) (DiMasi, et al 1991; OTA 1993) . Between 1994 and 2000 the real cost of capital for the pharmaceutical industry, using the CAPM model, varies from 10.6% to 12.0%, with a mean just over 11% (DiMasi et al, 2003) . The study uses a discount rate of 11%.
Patents have a limited life. Therefore the valuation of patents does not include a terminal value. In addition, the product life-cycles of drugs have been shortening since the 1980s (Grabowski and Vernon, 1990) . From 25 years in the 1970s, the drug life-cycle is estimated to be 20 years (Grabowski, Vernon and DiMasi, 2002) . Over the life-cycle, product sales are a function of patents and entry time into the market. Historically, patents commence prior to drug introduction to the market (Grabowski, et al., 2011) . 
Forecast Drug Product Sales Revenue
To forecast drug product sales revenue we first model historical sales revenue. The distribution of sales revenue is derived from the data and selected according to fit statistics.
The literature indicates that drug product sales data are continuous, asymmetric, and have positive outliers which suggest a non-normal distribution.
Using a selected continuous probability distribution, we model historical sales revenue as a function of post-approval year or pre-expiry year, a multiple lag of sales revenue and company indicator variables. The limited life-cycle demands that modelled drug product sales increase then decrease. We expect a logarithmic or exponential distribution and the following model to best fit the data:
Where:
Sales Revenue is annual drug sales revenue of product j at time t.
Year is post-approval for sale year or pre-patent expiry year .
Company is an indicator variable.
The models of sales revenue are tested iteratively for significant variable coefficients. The results determine the number of lags of sales used in the model. Further, for drug products with short data series we use supplementary estimation of sales revenue using one-year and two-year lags of sales revenue at each post-approval year and pre-expiry year. The models are augmented with an autoregressive model of the random error term to correct for serial correlation.
The model (2) and (3) 
Individual Product Expenses
The expenses attributable to individual drug products are not generally reported in financial statements. Therefore we estimate free cash flows from forecast sales revenue by estimating outgoings associated with pharmaceutical products. The estimates are initially guided by the literature before sensitivity testing.
Contribution Margin and Free Cash Flows
A drug's contribution margin, the unit revenue minus unit production and distribution costs, is first used to estimate free cash flows. That is, sales are multiplied by a contribution margin to estimate the free cash flow. Pharmaceutical contribution margins between 1973
and 1987 varied between 33% and 40% (Grabowski and Vernon, 1990) . More recent estimates of the mean contribution margins are 45% over the 20 year life cycle of the drug (Grabowski Vernon and DiMasi, 2002) and we initially adopt the 45% margin. In addition to the variable costs of production and distribution, pharmaceutical products incur additional expenses in R&D, marketing and capital investment as follows:
R&D -A survey of ten multinational pharmaceutical companies show that companies spent approximately 15% of R&D expenditures on improvements to drugs that have already been approved (DiMasi, Hansen and Grabowski, 2003) . R&D expenditures are apportioned to forecasted drug sales based on the ratio of reported company R&D expense to total sales revenue of the company. (2002) and Healy Myers and Howe (2002) indicate that the drug industry's marketing expenses to sales ratios vary over the drug life-cycle finishing at 6.5%. For calculating net present values in a low inflation environment 6.5% is adopted.
Marketing -Rosenthal Berndt and Donohue
Capital Investment -Grabowski Vernon and DiMasi (2002) calculate an average capital investment to sales ratio of 3.3% over the full product life cycle, generally consistent with data from pharmaceutical industry income statements.
Tax Rate: The average effective U.S. tax rate of a sample of 66 new chemical entities (NCEs) in the 1990s is 30% (Grabowski Vernon and DiMasi, 2002) . We adopt a tax rate of 30%.
The Valuation of R&D Capital
We examine how the income-based valuation of pharmaceutical patents compares with reported intangible assets and other attempts to value intangible assets. An alternative measure of intangible assets, R&D capital, is estimated from current and past R&D expenditure (Lev and Sougiannis, 1999; Chan et al., 2001) :
The coefficients α k are the unamortised portion of annual R&D expenditures and are estimated by two methods. The first method estimates the amortisation rate using a yearly cross sectional regression of company i:
OI is annual operating income before depreciation, advertising and R&D expenses at year t-1. TA is tangible assets, the value of property plant, and equipment, inventory, goodwill and investment in associated companies at year t-1. R&D Expense is annual R&D expenditure at year t-k. Ad Expense is annual advertising expenses at year t-1. All variables are scaled by annual sales to mitigate heteroscedasticity.
The amortisation rate for each year δ k is the ratio of α k / ∑α k :: which is the ratio of benefits expired in year t to total benefits of the R&D expenditure (Lev and Sougiannis, 1999) . Pooled and annual samples are tested to estimate amortisation rates. Calculating the amortisation rate δ k results in the following estimation of R&D Capital:
The advertising expense variable in model (5) 
The Value Relevance of Pharmaceutical Intangibles
Following the multiple valuation of intangible assets, we analyse the value-relevance of intangible assets where value relevance is the absorption of intangible asset information into stock price. The model in Ohlson (1995) models stock price (Price) for firm i at time t as a function of book value of equity (BVE), and net income (NetIncome). The terms α and ɛ capture the amount of price unexplained by BVE and net income.
We use a modified Barth and Clinch (1998) model of firm value using the valuations of intangible assets (INTANGIBLE) for company i with the added controls for book value and income:
Value is the market value of company i three months after the fiscal year-end t, measured by the product of stock price and the number of outstanding shares.
Book value of equity (BVE)
is measured as the reported value of net assets less total intangible assets at fiscal year-end t for company i.
Net income is reported (GAAP) net income before extraordinary items at fiscal yearend t for company i.
Intangible is measured as the value of R&D Capital, and the value of patents and drugs less acquired intangible assets, at fiscal year-end t for company i.
The study predicts all model (9) coefficients to be positive. As a sensitivity test, model (9) is re-estimated using variables scaled by the number of shares outstanding. Finally, the study performs Vuong (1989) and Clarke (2001) tests to compare the additional explanatory power of alternative measures of intangible assets in model (9).
Empirical Analysis

Sample and Data
The sample comprises the 60 largest stock-exchange listed pharmaceutical companies ranked by market capitalisation in US dollars between 2002 and 2012 with at least two years price and financial report data. Prices, currency rates, and financial report data are obtained Figure 2 shows two plots of product sales revenue against post-approval year and preexpiry year. In figure 2 , the blue observations show the existence of drug sales revenue before US FDA approval for sale indicating foreign sales. Further, the red observations show large sales revenues after patent expiry year, indicating multiple patents by dosage and foreign patents. Overall, the plots of sales revenues by both post-approval year and pre-expiry year are consistent with the 20 year life-cycle of most drugs (Grabowski et al. 2002) .
[insert figure 2 here ]
Likelihood-based statistics of fit including Akaike's information criterion and Schwarz Bayesian information criterion indicate that the sample is best modelled by a burr distribution. Using the burr distribution we iteratively model sales revenue with multiple lags of sales revenue, year, and company indicator variables. The coefficient estimates in Table 1 are then used to forecast sales in model (2). The forecasted product sales revenues are illustrated in figure 3 . The forecasted distribution is consistent with the historical distribution of product sales revenues, a 20 year drug life-cycle, with a delayed decline in sales post-patent expiry.
[insert figure 3 here ]
The forecast sales are used to estimate free cash flows and drug patent valuations. Figure 4 illustrates the size and distribution of drug patent valuations into 31 pharmaceutical companies. The distribution confirms the existence of outlier blockbuster drugs patented by larger pharmaceutical companies.
[insert figure 4 here ]
R&D Capital Amortisation and Valuation
In general, the lengthy lead period between R&D expenditure and economic benefits in the pharmaceutical industry raises the possibility that model (5), with operating income (OI) as the dependent variable, may not accurately estimate amortisation rates for R&D. In addition, many smaller companies report an annual operating loss before and after depreciation, advertising and R&D expenses. The loss companies create a negative association between R&D and OI over the full sample of pharmaceutical companies.
Nevertheless, significant coefficients in model (5) result from testing a subsample of operating profit companies using a simple one period lag R&D model. Adding advertising expense to model (5) reduces the sample size to US reporting companies and results in insignificant coefficients on R&D or lag R&D variables. Hence advertising expense is omitted from model (5). Table 2 presents ordinary least squares estimates of the R&D amortisation model (5) which examines the contributions of tangible and intangible assets to operating income. The R&D and the lag of R&D coefficients are both significant. The negative coefficient on tangible assets which is significant at the 5% level indicates that pharmaceutical firms with a higher proportion of tangible assets perform less profitably. Firms in the sample operate beyond pharmaceuticals in biotechnology, diagnostics and medical device segments.
[insert table 2 here ]
The R&D amortisation results of testing a large pharmaceutical company sample and a positive operating profit sample are similar. The operating profit sample produces a very high amortisation rate of 98% in the current year compared to an amortisation rate of 83% for large companies. The difference in amortisation rates is the result of large differences in the coefficient values of R&D and lag R&D variables. The lower amortisation rate is chosen from the large pharmaceutical company sample. 
Descriptive Statistics Drug Product Sales Revenue and Pharmaceutical Company
Table 3 presents descriptive statistics using the sample of 60 pharmaceutical companies and a sample of 539 drug products. The difference between mean and median product sales revenue is consistent with a number of outlier observations. For forecast drug sales revenues the lower mean and higher median is consistent with the extended forecast period beyond patent expiry. The mean drug patent valuations include drugs close to patent expiry and are only marginally higher than sales revenues. Further, Table 3 presents descriptive statistics for variables in value-relevance model (9). The company patent valuations have a higher median but lower mean than total intangible assets which is consistent with total intangible assets containing acquired R&D and other intangibles such as goodwill. Finally, Table 3 presents descriptive statistics for three sales and valuation ratios: the ratio of drug product sales revenues to company sales revenues, and the ratios of company patent valuation to total assets and to reported intangible assets.
The statistics indicate a number of pharmaceutical companies disclose low patented drug revenues and few intangible assets. Most of the low-disclosure companies are Japanese. The correlations are generally strong. BVE has relatively weaker correlation with patent valuation which suggests that intangible outputs are less predictable from the firm's recorded assets. 
Results
Vuong and Clarke Tests
The study also tests company patent valuations, R&D capital and reported intangible assets in alternate models to explain market value. Vuong (1989) and Clarke (2001) test the null hypothesis that both models are equally distant from the true model against the two-sided alternative that one model is closer to the true model. 
Additional Tests
Descriptive statistics indicate a number of low-disclosure companies with low patented drug sales and few intangible assets. The financial reports of these companies confirm active pipelines of R&D and exclude the companies as generic drug manufacturers, yet patented drug sales disclosure is low. Additional tests are conducted on a subsample of companies with disclosed product sales to total sales ratios above one third. We expect patents to be more important for companies whose patented drug sales are a higher proportion of total sales. 
Conclusion
We use a unique opportunity to value intangible assets from a time-series of cash flow outputs traceable to identifiable and separable intangible assets. As predicted we find that pharmaceutical sales revenues have a non-linear distribution with a drug life-cycle approaching 20 years.
There are two main findings. First, the valuation of patents for large pharmaceutical companies is value-relevant for companies with reported drug product sales that exceed one third of total revenues. Further, the minimum value of patents is one half of the minimum value of the R&D capital (CLS) estimation. The results suggest that patent valuation from cash flows better incorporates the risks of R&D investment as the R&D capital valuation models assume economic recovery of R&D expenditure whereas patent valuation makes no such assumption.
Second, we find that patent valuation models are preferred to reported intangible assets and R&D capital in explaining market value for large pharmaceutical companies.
Further, we fail to find an association between R&D capital and company value for large pharmaceutical companies. The results are consistent with the risky nature of R&D activity and the skewed distribution of returns to R&D activity in the pharmaceutical industry (Grabowski, et al, 2002) .
We contribute to the debate over the recognition of intangible assets and indicate conditions when asset recognition may be verifiable and relevant. The results although mixed also provide evidence on the benefits of the voluntary disclosure of product sales. The usefulness of intangible asset information is potentially high in the pharmaceutical industry because of information asymmetry and the lengthy drug discovery and development process (DiMasi, et al, 1991) .
We also contribute to the valuation of intangible assets and the economics of pharmaceuticals. The implication of the results for pharmaceutical companies is that the presentation of sales revenue information can assist the valuation of assets and the price discovery of stocks. The implication of the results for investors and banks is that the discounted cash flow method of valuing intangible assets is more useful in assessing the financial position of pharmaceutical companies than other methods of valuation.
Finally, one area of future research is to assess other capital market effects of the voluntary disclosure of intangible asset information such as reduced information asymmetry and reduced cost of capital. The disclosure literature also suggests a market reaction to credible commitments by companies to volunteer information. Drug Product Sales Revenue is reported annual USD drug product revenue at financial year end. Year 0 is US FDA drug approval for sale year (blue observations) and expiry year of earliest US FDA drug patent (red observations). 2774 observations are common to both blue and red samples. .
Figure 3 Plot of Forecast Drug Product Sales Revenue (USD) versus forecast year (n= 9537 observations).
Sales Revenue is forecast annual USD drug product revenue at financial year end for forecast years 1 to 40 inclusive; forecast Year is year of estimated sales.
Figure 4 Plot of Drug patent valuation (USD) by Company (n=539 observations).
Drug patent valuation is the sum of future drug cash flows discounted at 0.11 to patent expiry or to 15 years post-approval. OI is annual operating income before depreciation, advertising and R&D expenses at year t; TA is tangible assets, the value of property plant, and equipment, inventory, goodwill and investment in associated companies at year t-1; R&D is annual R&D expenditure at year t. All variables are scaled by annual net sales at year t. The coefficient is reported above the t statistic. *** significant at 1 per cent level; ** significant at 5 per cent level. 
Figure 5 Plot of R&D Capital (CLS) valuation (USD) by Company (n=278 observations).
; Value is absolute close market price of common stock at financial year end multiplied by common stock outstanding; BVE is fiscal year end common equity; Net Income is income before extraordinary items at financial year end t; Intangibles is reported total intangible assets at financial year end t; Drug/totalsales is drug product sales revenue divided by sales revenue at financial year end t; Patent/totalassets is company patent valuation divided by total assets at financial year end t; Patent/intangibles is company patent valuation divided by intangibles at financial year end t. 
Spearman Correlations
Value is absolute close market price of common stock at financial year end multiplied by common stock outstanding; BVE is fiscal year end common equity; Net Income is income before extraordinary items; Company patent valuation is the company aggregate of future drug cash flows discounted at 0.11 to patent expiry or to 15 years post-approval; Intangibles is reported total intangible assets at financial year end t; R&D Capital (LS) is Lev & Sougiannis (1999) Value is absolute close market price of common stock at financial year end multiplied by common stock outstanding; BVE is fiscal year end common equity minus total reported intangible assets; Net Income is income before extraordinary items; Company patent valuation is the company aggregate of future drug cash flows discounted at 0.11 to patent expiry or to 15 years post-approval; intangibles is reported total intangible assets at financial year end t; R&D Capital (LS) is Lev & Sougiannis (1999) Value is absolute close market price of common stock at financial year end multiplied by common stock outstanding; BVE is fiscal year end common equity minus total reported intangible assets; Net Income is income before extraordinary items; Company patent valuation is the company aggregate of future drug cash flows discounted at 0.11 to patent expiry or to 15 years post-approval; Intangibles is reported total intangible assets at financial year end t; R&D Capital (LS) is Lev & Sougiannis (1999) estimation of company R&D Capital; R&D Capital (CLS) is Chan, Lakonishok & Sougiannis (2001) estimation of company R&D Capital. Coefficient reported above t statistic; *** significant at 1 per cent level; ** significant at 5 per cent level; * significant at 10 per cent level.
